Incretin-based therapies for treatment of obesity The concept of incretin-based treatment of overweight and obesity was driven by the effect of native GLP-1 and GLP-1R agonists on appetite and satiety in combination with an observed loss in body weight in trials investigating liraglutide for the treatment of type 2 diabetes [27]
Tirzepatide may also improve insulin sensitivity more effectively than semaglutide, which targets only GLP-1
The former mainly include sulfonylureas, glinides, dipeptidyl peptidase-IV inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the latter mainly include biguanides, thiazolidinediones (TZDs), -glucosidase inhibitors, and sodium-glucose cotransport-2 inhibitors (SGLT-2i)
Blood 117 , e207e217 (2011)
The manufacturer Novo Nordisk holds patents on semaglutide formulations, which means true generic versionsbioequivalent copies produced by other manufacturersare not yet legally available in the United States
